Salmon calcitonin nasal spray can not be used in the treatment of early and late postmenopausal osteoporosis with conventional estrogen/calcium combination. In order to prevent progressive bone loss, patients who use this medicine must supplement appropriate amounts of calcium and vitamin D as needed. Massive osteolysis caused by bone metastasis of breast cancer, lung or kidney cancer, myeloma and other malignant tumors, deformed osteitis caused by hyperparathyroidism, inactivity or vitamin D poisoning (including acute or chronic poisoning), hypercalcemia and hypercalcemia crisis. Painful dystrophy or Sudeck's disease is often accompanied by various causes and predisposing factors, such as traumatic painful osteoporosis, sympathetic reflex, shoulder-arm syndrome, burning pain and iatrogenic dystrophy. Usage and dosage Osteoporosis nasal spray: 200 IU daily or every other day. Injection: 50 IU daily, or every other day 100 IU, subcutaneous or intramuscular injection. 50 IU every other day after 2-4 weeks. Osteoarthritis deformans is injected subcutaneously or intramuscularly every day 100 iu. After the clinical symptoms and signs are improved, 50 iu can be injected every other day or every day. If necessary, the daily dose can be increased to 200 iu. Nasal medication, a few cases may need 200 iu, twice a day. Emergency treatment of hypercalcemia hypercalcemia crisis 5- 10 iu/kg/ day, dissolved in 500 mL physiological saline, intravenous drip for at least 6 hours or slow intravenous injection in 2-4 doses per day, and supplemented with liquid. After emergency treatment, special treatment should be given to the primary disease. For the long-term treatment of chronic hypercalcemia, the dosage is 5- 10 iu/kg/ day, 1 time or twice subcutaneous or intramuscular injection. If the injection dose exceeds 2 mL, it should be injected intramuscularly in different parts. It can also be administered intranasally in fractions of 200-400 iu per day. Painful dystrophy was injected subcutaneously or intramuscularly, 100 iu per day for 2-4 weeks, and then 100 iu per time, three times per week for more than 6 weeks. Intranasal administration is 200 iu daily, divided into 2-4 times for 2-4 weeks, and then 200 iu each time, 3 times a week, for more than 6 weeks. The common adverse reactions are nausea, vomiting, dizziness and facial flushing, which are related to the dosage. Occasionally, polyuria and chills may occur, and the drug dosage may be temporarily reduced if necessary. Rare local or systemic allergic reactions. Precautions: It takes several months or even years to treat deformational osteopathy and other chronic diseases with increased bone turnover. Serum alkaline phosphatase and urinary hydroxyproline excretion decreased significantly, usually to normal levels, and the pain was completely relieved, however, it occasionally decreased and then increased. At this time, we should decide whether to continue the treatment according to the clinical manifestations. If the drug is stopped, the abnormal bone metabolism may recur after 1-2 months, and the drug needs to be used again. Long-term use of this drug can produce antibodies, but it usually does not affect the clinical efficacy of the drug. Long-term use can also cause drug failure ("escape phenomenon"), which may be caused by saturation of the binding site, and has nothing to do with antibody production. After stopping using the drug, the therapeutic response of calcitonin can be restored. Chronic rhinitis can increase the bioavailability of intranasal use of this drug, so patients with chronic rhinitis should use it with caution.